Takeda Pharmaceutical's Stock Ticks Higher as Q1 Sales Almost Flat At Constant Currency; Expects Headwinds For Rest Of 2023
Portfolio Pulse from Vandana Singh
Takeda Pharmaceutical Co Ltd's Q1 FY23 net profit rose 4.1% to ¥233.4 billion, driven by Growth & Launch Products. The company reported Q1 sales of ¥1,058.6 billion, up 8.9% at the actual exchange rate (AER), and +3.7% at the constant exchange rate (CER). Takeda's CFO, Costa Saroukos, anticipates headwinds affecting the business this fiscal year, largely due to generic competition. Takeda recently withdrew its FDA application for dengue vaccine approval due to data collection issues.
July 27, 2023 | 2:56 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Takeda's Q1 FY23 net profit rose 4.1% to ¥233.4 billion, driven by Growth & Launch Products. The company anticipates headwinds this fiscal year due to generic competition.
Takeda's Q1 FY23 results were positive with a 4.1% rise in net profit. However, the company anticipates headwinds this fiscal year due to generic competition, which could impact the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100